For decades, magnetic resonance imaging (MRI) has been the cornerstone of monitoring disease activity in multiple sclerosis (MS) in clinical practice mainly through the use of conventional measures thought to primarily represent inflammatory activity, including new/enlarging T2 lesions and/or gadolinium (Gd)-enhancing lesions. This forms the basis for the role of MRI in the surveillance of MS patients, monitoring of subclinical disease activity and assessing response to disease-modifying therapies (DMTs).
Controversy
For decades, magnetic resonance imaging (MRI) has been the cornerstone of monitoring disease activity in multiple sclerosis (MS) in clinical practice mainly through the use of conventional measures thought to primarily represent inflammatory activity, including new/enlarging T2 lesions and/or gadolinium (Gd)-enhancing lesions. This forms the basis for the role of MRI in the surveillance of MS patients, monitoring of subclinical disease activity and assessing response to disease-modifying therapies (DMTs).
Optical coherence tomography (OCT) is an imaging technique that allows rapid and non-invasive acquisition of high-resolution, cross-sectional images of the retina, from which quantitative measures of the retina's constituent layers can be derived with the application of validated, automated segmentation algorithms. Extensive progress over the past decade has been made in the in vivo study of the retina in MS utilizing OCT. OCT research in MS has mainly focused on measures of the inner retinal layers, namely, the macular ganglion cell + inner plexiform layer (GCIP) and peri-papillary retinal nerve fiber layer (RNFL), which mainly represent the integrity of ganglion neuronal cell bodies and their axons, respectively. It has been clearly established that GCIP and RNFL thinning are almost universal in MS relative to healthy controls, involve eyes with and without a history of optic neuritis (ON), and may be detectable at early stages of the disease. 1 Given the rapidly expanding body of literature supporting that GCIP and RNFL thinning is associated with global disability and disease activity in MS, it has been proposed that these measures may be used as an alternative to MRI for monitoring patients with MS. 2 Generally, for a biomarker to be useful in the monitoring of a chronic disease, it must exhibit the following attributes: (1) safety, (2) feasibility, (3) reasonable cost, (4) excellent reproducibility, (5) correlation with established clinical and paraclinical measures of disease activity/progression, and (6) correlation with therapeutic efficacy. OCT-derived measures have been demonstrated to fulfill all of these parameters. First, OCT is an extremely safe, non-invasive procedure that can be readily performed in an office-based setting, does not require any special precautions or administration of pharmacologic agents (including pupillary dilation), takes only a few minutes of scanning time, and is relatively inexpensive, especially when compared to the cost of MRI scans. Additionally, reproducibility of spectral-domain OCT-derived quantitative measures have been shown to be excellent in MS patients, and standardized quality control criteria have been validated to ensure reproducibility across centers. [3] [4] [5] In regards to the association of OCT-derived measures with established clinical and paraclinical measures of MS disease activity, inner retinal layer thinning is correlated cross-sectionally with global disability measures, as well as with brain volumes and quantitative spinal cord MRI measures. [6] [7] [8] Furthermore, longitudinal studies have found that baseline RNFL thickness of non-ON MS eyes predicts subsequent disability progression and that accelerated rates of inner retinal layer atrophy are associated with inflammatory disease activity (as evidenced by relapses, new/enlarging T2 lesions, and/or Gd-enhancing lesions), disability progression, and rates of brain atrophy (particularly of the gray matter) during follow-up. [9] [10] [11] Moreover, a recent study showed that use of natalizumab was associated with normalization of rates of GCIP atrophy to those observed in healthy controls, whereas use of conventional injectable DMTs such as glatiramer acetate and beta-interferons was associated with faster rates of GCIP atrophy. These findings indicate that OCT-derived measures are capable of demonstrating the differential therapeutic efficacy of MS DMTs in clinical practice. 12 Despite the strong associations of GCIP and RNFL atrophy with conventional MRI measures, these parameters inherently represent different pathologic processes. Conventional 
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inflammatory disease activity, whereas GCIP and RNFL thickness reductions/atrophy are representative of irreversible neuro-axonal loss, which is thought to represent the pathological substrate underlying permanent neurological disability in MS. This is an important distinction and highlights the utility of OCT not only as an alternative imaging modality for surveillance of disease activity, but also its ability to provide complementary information to MRI regarding the neurodegenerative aspect of MS, which may be especially useful for monitoring patients in the progressive stage of the disease. This is critical given that non-conventional MRI measures developed to assess neurodegeneration in MS, such as whole brain atrophy, despite extensive use in clinical trials, have not made their way into MS clinical practice due to a variety of reasons including pseudoatrophy and technical factors that limit their reliability at an individual level. 13 On the other hand one could argue that since OCT measures reflect the end result of the underlying inflammatory disease process, there may be a delay in identifying inflammatory activity prior to its culmination in irreversible tissue loss which could delay the implementation of earlier aggressive intervention. However, the use of OCT-derived measures of deeper retinal layers has recently been proposed to potentially address this possible shortcoming. Notably, the inner nuclear layer (INL) appears to exhibit thickening in association with inflammatory disease activity, as evidenced by positive associations between INL thickness at baseline with T2-lesion volume crosssectionally, as well as subsequent clinico-radiological disease activity during follow-up. 7, 14, 15 Furthermore, reductions in INL volume have been shown to be associated with a favorable response to DMTs. 15 It is clear, however, that these findings need to be validated further in larger scale studies.
In summary, there is ample evidence that supports the use of OCT for clinical monitoring in MS, given that OCT-derived measures mirror both clinical and MRI outcomes of the disease. Realistically, we do not expect that OCT can completely replace MRI in clinical practice for monitoring MS disease activity, but it does serve an important complementary role to MRI in the surveillance of MS, providing additional useful reliable and quantitative information, particularly regarding neurodegeneration, that is currently challenging to derive with conventional MRI. However, when taking into consideration the feasibility and low-cost of OCT, we do envisage a paradigm in which patients may be monitored with OCT on a more frequent basis (in addition to MRI), with detection of abnormalities more readily prompting further paraclinical evaluation and/or therapeutic action.
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OCT is an alternative to MRI for monitoring MS -NO Fahmy Aboulenein-Djamshidian and Nermin Serbecic
Despite tremendous scientific efforts, the cause of multiple sclerosis (MS) and, most importantly, its pathogenetic mechanisms are still unknown. At the moment, we only know that the application of certain immunotherapeutic agents may improve, but also may worsen an individual disease course. However, a clear implication that MS is an autoimmune disease cannot necessarily been drawn, although much of the published data would be in support of this view. Basically, we do not even know if MS is an unique disease with different subtypes, or if MS is a syndrome comprising different disease entities and disorders. We must be aware that we know only little. It is clear that empirical medical evidence has its limits and that we must not over-interpret our data and statistical associations.
By general agreement MS is a clinical diagnosis which is supported by a few paraclinical findings, in particular, such as cerebrospinal fluid (CSF) analysis and magnetic resonance imaging (MRI). The clinical symptoms, the chronic inflammatory CSF syndrome, and the MRI lesions are non-specific and only in their entire constellation suggestive for MS, but they must be no better explained by anything else. 1,2 However, every neurologist is well advised to support the clinical diagnosis of MS by MRI. It would be negligent not to do this, because the MRI provides, in contrast to OCT, a good overview of the brain and spinal cord and thus allows a very good differential diagnosis. 3 As the MRI is highly sensitive for monitoring disease activity, it is regarded as surrogate. In particular, the MRI is meaningful when the size or the number of lesions increases, or gadolinium enhancement or atrophy is found, and may require a change in treatment, even if the patient is asymptomatic. Vice versa, if no gadolinium enhancement or atrophy could be found, or the size and numbers of lesions decrease or even disappear, it might suggest that the disease activity is below the detection limit or that disease activity spontaneously passes by and that repair mechanisms fully work or that that the therapy is effective. Probably, the biggest advantage of the MRI is that the entire brain and spinal cord and their changes can be displayed in vivo, thus it allows neurologists to look inside their patients.
In contrast to MRI, the possible uses of OCT are more limited as it allows, from a strict scientific point of view, only a scan of the retina and measurement of its total thickness/volume or of individual retinal layers.
